Oxford BioDynamics

OBD is a global biotech company advancing personalized healthcare by developing and commercializing #PrecisionMedicine tests for life-changing diseases.

[Oxford BioDynamics @OxBioDynamics]

Oxford BioDynamics (#OBD) signs first commercial agreement with a major pharmaceutical company for use of EpiSwitch® Orion, its cloud-based #3Dgenomics platform, as part of a biomarker discovery programme in inflammatory bowel disease (#IBD). @JNJNews
https://t.co/jIJgHPVB2E

[Oxford BioDynamics @OxBioDynamics]

Oxford BioDynamics (AIM: OBD), the 3D Genomics Company, is pleased to announce that CEO Richard Compton will present at the @YstoneAdvisory Private Investor Evening on 11 November, held at SEC Newgate in London.
Register: https://t.co/PBIq1dTOlD
#OBD #AIM #EpiSwitch #3DGenomics

[Oxford BioDynamics @OxBioDynamics]

Heading to #ASHG26? Genomics is great at generating sequences, less so at explaining them. EpiSwitch® Orion predicts 3D regulatory genome architecture from #WGS, so you can ask new questions of your data. Meet our CEO & CTO at #ASHG with the Mobile App. #OBD @GeneticsSociety

[Oxford BioDynamics @OxBioDynamics]

100 days in as CEO of Oxford BioDynamics (#OBD), Rich Compton sat down with us to talk about what’s surprised him and where he sees #3Dgenomics heading. Read the full conversation here 👉 https://t.co/KTyuHk9C1X
#PrecisionMedicine #Genomics @OxBioDynamics

[94percent.com @94percent_com]

Dr Garrett Pohlman presented "Urology Updates” at the Nebraska Academy of Family Physicians conference (#NAFP), highlighting how #EpiSwitchPSE is supporting earlier, high-fidelity #prostatecancer evaluation in everyday practice across #Nebraska.
#OBD #PSE @gpohlmanmd @NEBRAFP

[Bartu Ahiska @DrBartu]

The Sunday Times covered a study using #EpiSwitchOrion, #OBD's AI-enabled discovery platform. @thetimes spoke to Prof Pshezhetskiy of the #UEA Norwich Medical School about the work, and what it could mean for ME/CFS, long COVID, PTSD, RA, MS (paywalled): https://t.co/dgd0D1IxZ7

[94percent.com @94percent_com]

🎙️ Dr Garrett Pohlman joined Dr Tom Rogers on an episode of The Common Sense MD to discuss why #PSA doesn't tell the full #ProstateCancer story, and how #EpiSwitchPSE adds clarity before biopsy or imaging. https://t.co/4T1PBtNTI6
@OxBioDynamics #OBD #PSE #urology @gpohlmanmd

[Oxford BioDynamics @OxBioDynamics]

Oxford BioDynamics partners with Dubai London Clinics & Hospitals to bring #EpiSwitchPSE to the UAE, our first commercial partnership for the #prostatecancer detection test in the Gulf region. Read more: https://t.co/HS9rzjqmHO

#OBD #PSE #urology #UAE #Dubai @94percent_com

[Oxford BioDynamics @OxBioDynamics]

#OBD CSO Dr Akoulitchev discusses how #EpiSwitch #3Dgenomics was applied to #MECFS. The unique signature that we found distinguished severe chronic fatigue syndrome from healthy controls with 96% accuracy in a study published in the Journal of Trans Med: https://t.co/GROYCBMFg8

[Oxford BioDynamics @OxBioDynamics]

We are pleased to announce today that the company (#OBD) has raised £9.15 million with new and existing institutional and other investors, subject to shareholder approval. Read more here: https://t.co/dIKhE152qz

[Oxford BioDynamics @OxBioDynamics]

#OBD announces its first commercial agreement for EpiSwitch Orion, supporting the OPTIMISE psoriatic arthritis research programme funded by @DHSCgovuk via @NIHRresearch with @UniofOxford @OxfordMedSci @ndorms, @UofGlasgow, @KingsCollegeLon and @GSTTnhs.
👉 https://t.co/pZAgHU5W8s

[Oxford BioDynamics @OxBioDynamics]

"What I've Learned from More Than 500 PSE Orders"
— We sat down with Dr @gpohlmanmd, board-certified #urologist and an experienced clinical user of #EpiSwitchPSE. He covers how #PSE fits into #prostatecancer evaluation 👇
https://t.co/SKM93OArIt

@94percent_com #OBD #urology #ad

[94percent.com @94percent_com]

We've partnered with MK Commercial Group, a specialist #lifesciences commercialisation organisation, to extend @OxBioDynamics' US commercial presence and drive growth of #EpiSwitchPSE. Read more: https://t.co/tvA2qF7O6l

#OBD #AIM #EpiSwitch #PSE #diagnostics #urology

[Oxford BioDynamics @OxBioDynamics]

We're pleased to announce the appointment of Richard Compton as CEO of Oxford BioDynamics. The former Oxford Nanopore and Illumina commercial executive has been appointed to lead the next phase of #OBD's development. Read more: https://t.co/Gku9vDA6IU

[Oxford BioDynamics @OxBioDynamics]

🎙️#EpiSwitchPSE featured on Health Uncensored with Dr. Drew.
Urologist @gpohlmanmd discussed how #PSE delivers a clear result with 94% accuracy from a blood draw, bringing clarity to the #prostatecancer diagnostic pathway.
Full story: 🔗https://t.co/HBAWUdvyVE
@94percent_com #OBD

[Oxford BioDynamics @OxBioDynamics]

🇺🇸 #Hiring: Clinical Lab Associate II | Frederick, MD.
Join Oxford BioDynamics' US lab, home of the #EpiSwitchPSE 94% accurate prostate cancer detection test. Apply 👉 https://t.co/RGLgXuhfmh
#OBD #EpiSwitch #BiotechJobs #ClinicalLab @94percent_com

[Oxford BioDynamics @OxBioDynamics]

#EpiSwitchPSE featured on Health Uncensored with Dr. Drew—now on YouTube. The advanced, 94% accurate blood test built to bring clarity to #prostatecancer detection.
▶️ Watch it here: https://t.co/OmuEVNNWtN
@94percent_com @HUwithDrDrew @FoxBusiness @gpohlmanmd #urology #OBD #PSE

[Garrett D Pohlman, M.D. @gpohlmanmd]

Honored to join Dr. Drew this evening (4 PM CST / 5 PM EST) on Fox Business Network’s - Dr. Drew’s Health Uncensored to discuss the evolving landscape of #ProstateCancer screening and detection.

[94percent.com @94percent_com]

This Sunday on @HUwithDrDrew: 3 in 4 raised PSA results aren't #prostatecancer. So what comes next?
—Urologist @gpohlmanmd shares what he's seeing using the breakthrough #EpiSwitchPSE test from @OxBioDynamics #OBD, shown to boost accuracy to 94%. 📺17 May 5pm ET @FoxBusiness #PSE